Literature DB >> 20449560

[New therapeutic approaches to special diseases of the small intestine].

M Schumann1, K Herrlinger, M Zeitz, E F Stange.   

Abstract

Numerous reports on fundamental research and clinical studies have appeared in the past 1-2 decades which have contributed decisively to understanding inflammatory diseases of the small intestine. Illustrated by the examples of Crohn's disease, celiac disease, refractory sprue, and Whipple's disease, the rationale and evidence for treatment approaches are presented that are based on these pathophysiological findings. Emphasis is placed on modulation of the intestinal flora with antibiotics and probiotics as well as immunomodulatory/immunosuppressive measures with so-called biological agents. Future treatment options that directly intervene in the disease process are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20449560     DOI: 10.1007/s00108-009-2568-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  65 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Clin Ther       Date:  2006-12       Impact factor: 3.393

4.  Treatment of refractory Whipple disease with interferon-gamma.

Authors:  T Schneider; A Stallmach; A von Herbay; T Marth; W Strober; M Zeitz
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

Review 5.  Probiotics for maintenance of remission in Crohn's disease.

Authors:  V E Rolfe; P J Fortun; C J Hawkey; F Bath-Hextall
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

6.  Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease.

Authors:  G A Doherty; G C Bennett; A S Cheifetz; A C Moss
Journal:  Aliment Pharmacol Ther       Date:  2010-01-04       Impact factor: 8.171

7.  A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.

Authors:  Sophie Hüe; Jean-Jacques Mention; Renato C Monteiro; ShaoLing Zhang; Christophe Cellier; Jacques Schmitz; Virginie Verkarre; Nassima Fodil; Seiamak Bahram; Nadine Cerf-Bensussan; Sophie Caillat-Zucman
Journal:  Immunity       Date:  2004-09       Impact factor: 31.745

Review 8.  New insights into Whipple's disease - a rare intestinal inflammatory disorder.

Authors:  Thomas Marth
Journal:  Dig Dis       Date:  2009-11-04       Impact factor: 2.404

Review 9.  Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials.

Authors:  Martin Feller; Karin Huwiler; Alain Schoepfer; Aijing Shang; Hansjakob Furrer; Matthias Egger
Journal:  Clin Infect Dis       Date:  2010-02-15       Impact factor: 9.079

10.  Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease.

Authors:  Jochen Klaus; Ulrike Spaniol; Guido Adler; Richard A Mason; Max Reinshagen; Christian von Tirpitz C
Journal:  BMC Gastroenterol       Date:  2009-07-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.